By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by

By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC Imagine yourself setting out to do business in Japan. You step off the plane, check into

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has brought unique challenges for growing companies.  Capital markets, shifting regulatory winds and other emergent forces are driving tough decisions on programs,

By René Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC I had the opportunity to witness true courage as I met Chrissy Harding several times before she passed away from advanced lung cancer.

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC  A couple of years ago, my husband returned from a business trip with a random gift for me. He was running through an airport

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Like many of you, I’m a consumer of biotech industry news. Multiple times of day I scour BioCentury, STAT,

Another day, another “restructuring” – there’s been a flurry of press releases recently using phrases like “exploring strategic alternatives”, “extending the cash runway”, and “de-prioritizing” certain R&D programs. These announcements are obviously responses to the tough market environment. In every

By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC Our company recently launched out of stealth with a trade media campaign in the usual outlets, which felt great until one article

While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem. Startups get formed, often in stealth, and

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives

There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market. I’ve read a good deal of venting covering this theme, including comments about VCs

Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing both the emerging tech and biotech sectors alike. Last year, generalists in many ways capitulated